SCHEMBL12688441

SCHEMBL12688441

CC(C)(C)OC(=O)N[C@H]1CC[C@@H](Sc2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
SMYD3 Q9H7B4 1/20 0.42
KCNA3 P22001 1/20 0.42
EPHX2 P34913 2/20 0.42
CCRL2 O00421 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
DRD2 P14416 4/20 0.41
CCR2 P41597 2/20 0.40
DRD3 P35462 1/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12688425 1.00 KDM1A (0.47) KDM1AMAOBPOLBHTTRXFP1
SCHEMBL1498387 0.90 KMT2A (0.45) KDM1AMAOBRXFP1KCNA3EPHX2
SCHEMBL12692937 0.90 KMT2A (0.45) KDM1AMAOBRXFP1KCNA3EPHX2
SCHEMBL1498389 0.90 KMT2A (0.45) KDM1AMAOBRXFP1KCNA3EPHX2
SCHEMBL12692962 0.85 DRD2 (0.45) KDM1AMAOBPOLBHTTSMYD3
SCHEMBL1498380 0.85 DRD2 (0.45) KDM1AMAOBPOLBHTTSMYD3
SCHEMBL1498381 0.85 DRD2 (0.45) KDM1AMAOBPOLBHTTSMYD3
SCHEMBL1498344 0.84 SMYD3 (0.46) POLBHTTSMYD3EPHX2MEN1
SCHEMBL1498342 0.84 SMYD3 (0.46) POLBHTTSMYD3EPHX2MEN1
SCHEMBL1498444 0.84 SMYD3 (0.46) POLBHTTSMYD3EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 US disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 US disclosed
WO-2011035159-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1A KDM1A 3502/4885MAOB 484/4885POLB 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.